Scientific Advisors – Wombat Capital

Extraordinary People Doing Extraordinary Things


Through our relationship with the strategic and scientific advisory firm, Wombat Capital, Ltd. we have access to its exceptional group of scientific and industry experts who all have a specific know-how in certain therapeutic fields or sub-sectors of the Life Sciences industry. These advisors will bring tremendous value to 'Q' assisting in the sourcing, review and evaluation of opportunities.

MEET OUR TEAM...they are always up to something good!

Andy Watson
Senior Advisor: Diagnostics, Companion Diagnostics, Genomics and Life Science Tools

  • Current Senior Advisor at Wombat Capital.
  • Current VP Corporate Development at Cell Signaling Technology, involved in companion diagnostic.
  • Former Senior Vice President and CCO at RainDance Technologies, a privately-held company with ultra-sensitive genomic tools that are leading to new non-invasive liquid biopsy applications for more accurate, reliable, cost-effective and early detection of cancer, inherited, and infectious diseases.
  • Former Vice President, Chief Marketing Officer and Head of Global Sales at RainDance Technologies.
  • Former Vice President SOLiD Systems Product Management at Life Technologies, a global biotechnology company with products in scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research.
  • Former Vice President Business Operations, Single Molecule Sequencing at Life Technologies.
  • Former Vice President Business Development and Vice President Systems Engineering at Quantum Dot Corporation, a privately held start-up, based on quantum dot nano-technology for bio-detection, later acquired by Invitrogen.
  • 16 patents and 10 peer reviewed publications on genomics, genetics, bio-detection, assays, and instrumentation.
  • Started his career at The Sanger Center and Medical Research Council in Cambridge, UK where he worked with Nobel Laureate John Sulston to create Europe’s premier genome center.
  • Grant and on-site reviewer for 9 National Institutes of Health sequencing technology grant programs.
  • Bachelors (1989) & Masters (1990) in Engineering with Business, King’s College, Cambridge University, UK.
  • Fluent in English
Dr. Geert Cauwenbergh
Senior Advisor: Skin Care, Dermatology, Wound Care, OTC, Infectious Diseases, Women’s Health

  • Current Senior Advisor at Wombat Capital.
  • Current CEO of RXI Pharmaceuticals, a biotechnology company pursuing the development of RNAi therapeutics for the treatment of neurodegenerative disease, diabetes and obesity.
  • Former CEO and Chairman of RHEI Pharmaceuticals, a company that in-licenses Western pharmaceutical products for the Chinese and SE Asian markets.
  • Founder of Barrier Therapeutics, a publicly traded R&D biopharmaceutical company focused on the treatment of skin diseases, then sold to Stiefel Laboratories (A GSK Company).
  • Former VP of Technology of the Johnson & Johnson Consumer and Personal Care Products Companies.
  • Former Global VP of R&D of the J&J Consumer Companies Worldwide and member of the J&J Business Development Council.
  • Former Director of the J&J Skin Care Council.
  • Member of the Board of Trustees and past Chairman of Bio New Jersey (2009 - 2010).
  • Former member of the Board of Trustees of the New Jersey Center of Life Sciences.
  • Trade Advisor for Healthcare in North America to the Belgian Government.
  • Former board member of Ablynx NV, Euroscreen SA and former Executive Chairman of ECI Biotech.
  • Inducted into the New Jersey High Tech Hall of Fame in 2004.
  • Extensive relationships and expertise in the Biotech, OTC, Skin Care, Wound Care, Women’s Health and Infectious Diseases sectors in North America and Europe.
  • Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine.
  • Fluent in English, French, German and Dutch.

Dr. Helga Grupe
Senior Advisor: Oncology

  • Current Senior Advisor at Wombat Capital.
  • Former Managing Director at Avontec GmbH.
  • Former VP Business Development at Wilex AG.
  • Over 20 years experience in the Life Sciences sector, including managerial positions at Monsanto GmbH and Zeneca GmbH.
  • Extensive relationships and expertise in the Oncology sector in North America and Europe.
  • Ph.D. Biology, Georg August Universität Göttingen.
  • Fluent in English and German.

Dr. Jose de Chastonay
Senior Advisor: Contract Services

  • Current Senior Advisor at Wombat Capital.
  • Current Chief Marketing Officer and Member of the Corporate Executive Committee of Bachem.
  • Former President and CEO of Irvine Scientific Sales Company Inc., company active in the fields of Assisted Reproductive Technologies, Cytogenetic Diagnostics and Industrial Cell Culture.
  • Former Member of the Board of Irvine Scientific Sales Company Inc.
  • Former President of Bachem Americas, the subsidiary of the leading Swiss fine chemicals company that makes and supplies research tools and manufactures bulk active pharmaceuticals for biotechnology and pharmaceutical companies.
  • Over 25 years experience in Life Sciences, including managerial positions at F. Hoffmann-La Roche AG, Basel-Diagnostic Division and Ares Serono.
  • Extensive relationships and expertise in the Pharmaceutical, Manufacturing (Fermentation, Cell Culture, APIs and Peptides), Vaccines, Generics and Medical Devices sectors in North America and Europe.
  • Accomplished virologist, having manufactured a veterinary rabies vaccine and conducted anti-viral compound studies.
  • Ph.D., Medical Microbiology, University of Bern, Switzerland and MBA, European University, Montreux, Switzerland.
  • Former Board member of Viroblock SA and former member of the Scientific Advisory Board of Rapid Pharmaceuticals AG.
  • Fluent in English, French and German.

Dr. Scott P. Bruder
Senior Advisor: Medical Device Orthopedics & Regenerative Medicine

  • Current Senior Advisor at Wombat Capital.
  • Principal, Bruder Consulting International, LLC.
  • Former Chief Medical and Scientific Officer, Stryker Corporation.
  • Former Senior Vice President and Chief Science and Technology Officer, Becton, Dickinson & Company.
  • Former Worldwide Vice President, Johnson & Johnson Regenerative Therapeutics, LLC.
  • Former Worldwide Vice President, DePuy Biologics.
  • Former Worldwide Vice President, Orthobiologics, DePuy AcroMed, DePuy Orthopaedics/ACE, and Mitek Worldwide.
  • Former Vice President, Orthobiologics, DePuy Inc.
  • Former Vice President R&D, Anika Therapeutics, Inc.
  • Started his career at Osiris Therapeutics, Inc. as a director of Bone and Soft Tissue Regeneration.
  • Professor, Department of Biomedical Engineering (Adjunct), Case Western University, Cleveland, OH.
  • Board of Directors and Vice President At-Large, American Institute for Medical and Biological Engineers (AIMBE).
  • FDA Advisory Committee on Cellular, Tissue and Gene Therapies, Bethesda, MD.
  • Industrial Advisory Board Member, New York Stem Cell Foundation, New York, NY.
  • Recent Awards: 2012, New Jersey Inventors Hall of Fame Award, for Research and Entrepreneurial Leadership; 2014, Prix Galien.Award, Medical Device Technology of the Year (TrevoProVue™); 2015, Pierre Galletti Award, American Institute for Medical and Biological Engineering (The highest honor that AIMBE bestows on an individual).
  • Ph.D. In Cell Biology from Case Western Reserve University, M.D. from Case Western Reserve University School of Medicine and B.Sc. From Brown University.
  • Fluent in English.
John Erb
Senior Advisor: Medical Device Cardio Vascular

  • Current Senior Advisor at Wombat Capital.
  • Current Chairman, CEO and Co-founder of NuAx, Inc., (diagnostic and therapeutic treatments in electrophysiology; also aerospace applications).
  • Current Chairman of publicly traded Vascular Solutions, Inc., (minimally invasive solutions for cardiologists and interventional radiologists).
  • Current Chairman of publicly traded Sunshine Heart, Inc., (therapeutic technology treating heart failure.
  • Current Chairman of publicly traded Osprey Medical, Inc., (treatment for contrast induced nephropathy in interventional cardiology patients).
  • Current Chairman of Osprey Medical, Inc. (treatment for contrast-induced nephropathy in interventional cardiology patients).
  • Member of the Board of Harbinger Medical, Inc. (diagnostic of sudden cardiac arrest).
  • Former member of the Board of publicly-traded SenoRx, Inc. (medical devices for the diagnosis and treatment of breast cancer). Acquired by CR Bard in 2010.
  • Former member of the Board of publicly-traded CryoCath Technologies, Inc. (cryo-therapy products for the treatment of cardiovascular disease). Acquired by Medtronic in 2008.
  • Former member of the Board of Xoft, Inc. (devices for the diagnosis and treatment in radiation oncology). Acquired by iCAD, Inc. in 2010.
  • Former Chairman of VivoMetrics, Inc. (diagnostic products for the pre-clinical pharmaceutical and patient monitoring markets).
  • Former CEO of CHF Solutions, Inc., acquired by Gambro in 2010 (focused on congestive heart failure).
  • Former CEO of IntraTherapeutics, Inc., (peripheral vascular stent products). Acquired by Sulzer Medica in 2001.
  • E&Y 2001 Entrepreneur of the Year in Technology for Minnesota and the Dakotas and finalist for the national Entrepreneur of the Year award.
  • Former VP of Worldwide Operations of Schneider Worldwide, a division of Pfizer, Inc. Acquired by Boston Scientific in 1998.
  • Former General Manager of Schneider U.S. Stent Division.
  • Previous management experience with American Hospital Supply Corp., Cutter Laboratories, Inc., and Johnson & Johnson.
  • Started his career at American Hospital Supply Corporation.
  • B.A. in Business Administration, from California State University.
  • Fluent in English.

MaryJane Rafii
Senior Advisor - Opthamology

  • Senior Director, Corporate Development and Strategy, Ora Inc, the world’s leading independent, full-service ophthalmic drug and device development firm with offices in the United States and Japan.
  • Played a key role in over 40 regulatory approvals in the US.
  • Co-founder and a Board Member of JADE Therapeutics, an ophthalmology focused company based in Salt Lake City, UT.
  • Served as Early Asset Lead at Pfizer Worldwide Research and Development in New York for all Ophthalmology, Neuroscience and Pain assets and also as a Medical Lead for the Specialty Care Business Unit
  • Prior to Pfizer, she served as Chief Medical Officer for Fovea Pharmaceuticals in Paris, which was successfully acquired by Sanofi Aventis in 2009.
  • Held executive roles at Bioenvision Inc. an oncology focused publicly traded company acquired by Genzyme as well as the Ludwig Institute for Cancer Research (LICR) and LifeCycle Pharma all based in New York City.
  • PhD from Cardiff University in Ophthalmology and a Master of Science in Biochemistry, Stanford University, Palo Alto,
  • Bachelor of Science in Molecular Biology, University of Southern California, Los Angeles, CA

brilliant MINDS think alike

and make the world a little bit better!

Social media & sharing icons powered by UltimatelySocial